Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer
about
Mechanisms underlying skin disorders induced by EGFR inhibitorsBiological agents in gastrointestinal cancers: adverse effects and their management.Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer.Assessment of frequency and severity of hypomagnesemia in patients with metastatic colorectal cancer treated with cetuximab, with a review of the literature.Management of dermatologic toxicities associated with monoclonal antibody epidermal growth factor receptor inhibitors: A case reviewEpidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management.Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer.Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence.Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational StudyEfficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.Kinase-targeted cancer therapies: progress, challenges and future directions.Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells.Identification of Ras-degrading small molecules that inhibit the transformation of colorectal cancer cells independent of β-catenin signaling.
P2860
Q26745689-196376E7-153F-40EE-8B87-E118DEAFBA7AQ33895581-E8B6745F-DA72-4C79-A548-CC1BE9FF4D75Q36321184-317DD17D-117B-4FC8-8299-3188BBB08D94Q36334196-44A29862-1BE0-48AF-B105-CCBCB02C9BB5Q37369678-F1CE7AB7-B75B-4917-BD21-5A1C17D0F169Q37644848-FF6B8026-1694-43D4-864F-FD177381CF88Q38175030-E1FD8F4B-CF31-4197-92B6-9BC2F503CDB2Q40971778-0926CA9B-2D8B-42DB-909A-89471277F4BFQ41439263-9A584608-F7B4-40DB-A907-E62BEF7F800AQ46008308-790F6188-34F9-400F-B8FC-4A0CE2BC4E6BQ49887882-F12F951E-C48A-4124-BA22-160A2CF86E65Q52658297-ADF4F5B9-040F-491F-9717-E081D48DE7FAQ52731753-00D8EB4B-AF68-4B03-98AE-F0ACC43D741BQ55272385-C114E8B2-47DD-4CFA-AB2D-BFFB79AA7EC7
P2860
Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Adverse events associated with ...... f metastatic colorectal cancer
@ast
Adverse events associated with ...... f metastatic colorectal cancer
@en
type
label
Adverse events associated with ...... f metastatic colorectal cancer
@ast
Adverse events associated with ...... f metastatic colorectal cancer
@en
prefLabel
Adverse events associated with ...... f metastatic colorectal cancer
@ast
Adverse events associated with ...... f metastatic colorectal cancer
@en
P2860
P1433
P1476
Adverse events associated with ...... f metastatic colorectal cancer
@en
P2093
P2860
P304
P478
17 Suppl 1
P577
2010-07-01T00:00:00Z